Price$8.31+2.43 (+41.21%)
2025-09-302026-01-02
News · 26 weeks140%
2025-12-072026-05-31
Mix090d
No activity.
Latest news
25 items- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRHELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on NasdaqHelus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company's ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market ("Nasdaq") and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists ("NSAs"), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma's NSA in Phase 3 clinical development,
- SECSEC Form CERT filed by Cybin Inc.CERT - CYBIN INC. (0001833141) (Filer)
- SECSEC Form 8-A12B filed by Cybin Inc.8-A12B - CYBIN INC. (0001833141) (Filer)
- SECSEC Form 25 filed by Cybin Inc.25 - CYBIN INC. (0001833141) (Filer)
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- SECSEC Form SUPPL filed by Cybin Inc.SUPPL - CYBIN INC. (0001833141) (Filer)
- PRCybin Initiates At-The-Market Equity Program of up to US$100 MillionCybin Inc. (NYSE:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has launched an at-the-market equity program (the "ATM Program") to allow Cybin to issue and sell up to US$100,000,000 of common shares in the capital of the Company (the "Shares") from treasury to the public, from time to time, through Cantor Fitzgerald and Co. and Cantor Fitzgerald Canada Corporation (together the "Agents"). All the Shares sold under the ATM Program will be sold in transactions that are deemed to be "at-the-market
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- SECSEC Form F-X filed by Cybin Inc.F-X - CYBIN INC. (0001833141) (Subject)
- SECSEC Form F-10 filed by Cybin Inc.F-10 - CYBIN INC. (0001833141) (Filer)
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRCybin to Transfer U.S. Stock Exchange Listing to NasdaqCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cybin Inc.SCHEDULE 13G/A - CYBIN INC. (0001833141) (Subject)
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRCybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights- Closed registered direct offering for aggregate gross proceeds of US$175 million (the "Registered Direct Offering") led by a syndicate of prominent biopharmaceutical institutional investors - - On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder ("GAD") in Q1 20261 - - Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder ("MDD") - -The Company's cash position as at September 30, 2025 after giving effect to the net proceeds of the Registered Direct Offering is US$248 million - - Repayment of outstanding convertible debentures to High Trail Special Situations LLC an
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRCybin to Participate in the Jefferies Global Healthcare Conference in LondonCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that George Tziras, Cybin's Chief Business Officer, will present at the Jefferies Global Healthcare Conference, taking place November 17-20, 2025, in London, UK. The presentation will be webcast live on Monday, November 17, 2025, at 12:30 p.m. GMT (7:30 a.m. ET). To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Even
- SECSEC Form SCHEDULE 13G filed by Cybin Inc.SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRCybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025- Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRCybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that George Tziras, Cybin's Chief Business Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10-12, 2025, in Boston, MA. The fireside chat will be webcast live on Monday, November 10, 2025, at 4:30 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relatio
CYBN FAQ
6 questionsWhat does Cybin Inc. do?
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program...Where does CYBN stock trade?
Cybin Inc. (CYBN) is listed on AMEX.What sector and industry is CYBN in?
Cybin Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CYBN?
Cybin Inc. has had 5 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $3500.00 price target on 2025-03-13. Recent price targets range from $700.00 to $3500.00.What companies are similar to CYBN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CYBN side-by-side with any of them on Quantisnow.How can I track CYBN on Quantisnow?
Quantisnow aggregates Cybin Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYBN to receive live email and push alerts on every new disclosure.